Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 12/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 5/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.56 |
| ▸ | TET3 | O43151 | 1/20 | 0.56 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476505 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2GRM1GRM2TET2 | |
| SCHEMBL3981383 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2GRM1GRM2TET2 | |
| Hydrochloric Acid SCHEMBL4186334 | 0.98 | GRIK1 (0.95) | GRIK1GRIK2GRM1GRM2TET2 | |
| Hydrochloric Acid SCHEMBL6235798 | 0.98 | GRIK1 (0.95) | GRIK1GRIK2GRM1GRM2TET2 | |
| Ammonia Solution, Strong SCHEMBL638403 | 0.98 | GRIK1 (0.95) | GRIK1GRIK2GRM1GRM2TET2 | |
| Lysine SCHEMBL7036667 | 0.83 | GRIK1 (0.69) | GRIK1GRIK2GRM1GRM2TET2 | |
| SCHEMBL1331822 | 0.83 | GRIK1 (0.71) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL1331820 | 0.83 | GRIK1 (0.71) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL5797481 | 0.81 | GRIK1 (0.68) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| Itaconate SCHEMBL27997562 | 0.81 | GRIK1 (0.67) | GRIK1GRIK2GRM1GRM2TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120000628-A | Application of 4-methylene glutamic acid in pharmacy | 桂林医学院附属医院 | 2025-05-16 | — | — | CN | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | claimed |
| CN-117750978-A | Synthetic peptide shuttle bioconjugates for intracellular cargo delivery | 费尔丹生物公司 | 2024-03-22 | — | — | CN | claimed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | claimed |
| CN-116615205-A | Peptide-based transduction of non-anionic polynucleotide analogs for modulation of gene expression | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| CN-116615227-A | Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| US-20220204561-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-06-30 | — | — | US | claimed |
| CN-114008210-A | Peptide-based non-protein cargo delivery | 费尔丹生物公司 | 2022-02-01 | — | — | CN | claimed |
| WO-1999036409-A1 | METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES | NAIR MADHAVAN G (US) | 1999-07-22 | — | — | WO | claimed |
| US-5912251-A | ENZYME INHIBITORS | CHELSEA THERAPEUTICS, INC. | 1999-06-15 | — | — | US | claimed |
| EP-0867430-A2 | Glutamic acid derivatives and pharmaceutical compositions for the treatment of central nervous system disorders | LILLY S.A. (ES) | 1998-09-30 | — | — | EP | claimed |
| CN-1136764-A | Flavouring compositions and its preparing method | FIRMENICH & CIE (CH) | 1996-11-27 | — | — | CN | claimed |
| US-5550128-A | ANTITUMOR AGENTS | NAIR, MADHAVAN G. | 1996-08-27 | — | — | US | claimed |
| EP-0513068-B1 | THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME | NAIR MADHAVAN G (US) | 1995-09-13 | — | — | EP | claimed |
| US-5369142-A | Curable mixtures with acrylic acid or methacrylic acid derivatives of amino acids | THE OHIO STATE UNIVERSITY (US) | 1994-11-29 | — | — | US | claimed |
| EP-0513068-A4 | THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME | — | 1993-06-30 | — | — | EP | claimed |
| EP-0513068-A1 | THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME. | NAIR MADHAVAN G (US) | 1992-11-19 | — | — | EP | claimed |
| WO-1991010666-A1 | THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME | NAIR MADHAVAN G (US) | 1991-07-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | SCAMP2, SLC7A1, NUMA1 | GRIK1 2487/4885GRIK2 2335/4885GRM1 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.